PAULA WAKI LOPES DA ROSA
Projetos de Pesquisa
Unidades Organizacionais
LIM/18 - Laboratório de Carboidratos e Radioimunoensaios, Hospital das Clínicas, Faculdade de Medicina
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
- Differences in the gut microbiota of women according to ultra- processed food consumption(2023) FERNANDES, Ariana E.; ROSA, Paula W. L.; MELO, Maria E.; MARTINS, Roberta C. R.; SANTIN, Fernanda G. O.; MOURA, Aline M. S. H.; COELHO, Graziele S. M. A.; SABINO, Ester C.; CERCATO, Cintia; MANCINI, Marcio C.Background and aims: High consumption of ultra-processed food (UPF) has been associated with increased risk of obesity and other metabolic diseases, and this dietary pattern seems to be responsible for chronic changes in the gut microbiota. The aim of this study was to assess the associations of UPF with the gut microbiota and obesity-associated biometrics in women. Methods and results: This cross-sectional study examined 59 women. The following parameters were evaluated: food consumption using NOVA classification, anthropometric and metabolic parameters, and gut microbiome by next-generation sequencing. The mean age was 28.0 & PLUSMN; 6.6 years. The mean caloric intake was 1624 & PLUSMN; 531 kcal, of which unprocessed or minimally processed food (G1) accounted for 52.4 & PLUSMN; 13.5%, and UPF accounted for 31.4 & PLUSMN; 13.6%. Leptin levels adjusted for fat mass were negatively associated with G1 and positively associated with UPF. We found 15 species in the gut microbiota that correlated with G1 (3 positively and 12 negatively) and 9 species associated with UPF (5 positively and 4 negatively). Conclusion: Higher consumption of UPF was directly associated with leptin resistance, and this study suggests that the consumption of UPF or G1 may affect the composition of the gut micro biota. & COPY; 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.
- Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial(2023) PONTE NETO, Alberto Machado da; CLEMENTE, Aniele Cristine Ott; ROSA, Paula Waki; RIBEIRO, Igor Braga; FUNARI, Mateus Pereira; NUNES, Gabriel Cairo; MOREIRA, Luana; SPARVOLI, Luiz Gustavo; CORTEZ, Ramon; TADDEI, Carla Romano; MANCINI, Marcio C.; MOURA, Eduardo Guimaraes Hourneaux deBACKGROUNDMetabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.AIMTo evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.METHODSThis was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.RESULTSThere was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.CONCLUSIONThere were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.